AstraZeneca to present new cardiovascular data on Farxiga in type-2 diabetes at ACC 2019

Click here to view online. Add this email to your safelist.

11 March 2019

Data evaluating the cardiovascular (CV) effects of Farxiga (dapagliflozin), including hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on 16-18 March. The data are the first sub-analyses from the Phase III DECLARE-TIMI 58 trial for Farxiga.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.